CHUGAI PHARMACEUTICAL CO., LTD. Logo

CHUGAI PHARMACEUTICAL CO., LTD.

A research-driven pharmaceutical company developing innovative medical products.

4519 | T

Overview

Corporate Details

ISIN(s):
JP3519400000
LEI:
Country:
Japan
Address:
北区浮間五丁目5番1号

Description

Chugai Pharmaceutical Co., Ltd. is a research and development-driven pharmaceutical company dedicated to creating innovative medical products to address unmet medical needs. As a member of the Roche Group, Chugai leverages its advanced expertise in biotechnology and science to develop novel treatments, establishing a leading position in therapeutic antibodies. The company's strategy emphasizes a shift towards discovery research and early clinical development, the integration of digital technologies, and open innovation through external partnerships. Its core therapeutic areas include oncology, rheumatology, and haemophilia, where it provides biopharmaceuticals and molecular targeted therapies to patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-25 08:42
確認書
Japanese 9.6 KB
2025-07-25 08:40
半期報告書-第115期(2025/01/01-2025/12/31)
Japanese 298.8 KB
2025-04-22 09:07
訂正臨時報告書
Japanese 39.1 KB
2025-03-28 06:43
臨時報告書
Japanese 27.8 KB
2025-03-27 08:12
臨時報告書
Japanese 39.7 KB
2025-03-27 07:57
内部統制報告書-第114期(2024/01/01-2024/12/31)
Japanese 24.8 KB
2025-03-27 07:50
確認書
Japanese 9.6 KB
2025-03-27 07:48
有価証券報告書-第114期(2024/01/01-2024/12/31)
Japanese 3.3 MB
2024-07-26 08:02
確認書
Japanese 9.6 KB
2024-07-26 08:01
半期報告書-第114期(2024/01/01-2024/12/31)
Japanese 330.6 KB
2024-07-26 07:35
確認書
Japanese 9.6 KB
2024-07-26 07:30
訂正有価証券報告書-第113期(2023/01/01-2023/12/31)
Japanese 1.8 MB
2024-04-25 08:09
確認書
Japanese 9.6 KB
2024-04-25 08:07
四半期報告書-第114期第1四半期(2024/01/01-2024/03/31)
Japanese 272.0 KB
2024-04-24 08:21
確認書
Japanese 9.6 KB

Automate Your Workflow. Get a real-time feed of all CHUGAI PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CHUGAI PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CHUGAI PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Camp4 Therapeutics Corp Logo
Develops RNA-based therapeutics to amplify protein expression for genetic diseases.
United States of America
CAMP
Camurus Logo
Develops and commercializes long-acting medicines for severe and chronic diseases.
Sweden
CAMX
Candel Therapeutics, Inc. Logo
Develops viral immunotherapies to activate the immune system to fight cancer.
United States of America
CADL
Can-Fite BioPharma Ltd. Logo
Clinical-stage biopharma developing oral small-molecule drugs targeting the A3AR.
Israel
CANF
Cannabotech Ltd. Logo
Develops therapies by integrating cannabinoids and medicinal mushroom extracts.
Israel
CNTC
Cannovum Cannabis AG Logo
Licensed importer, wholesaler, and manufacturer of medical cannabis products.
Germany
27N0
Cantargia Logo
Develops antibody therapies targeting IL1RAP for cancer and inflammatory diseases.
Sweden
CANTA
Cantourage Group SE Logo
Produces and distributes EU-compliant medical cannabis from international partners.
Germany
HIGH
CAPRICOR THERAPEUTICS, INC. Logo
A clinical-stage biotech developing cell and exosome-based biologics for serious diseases.
United States of America
CAPR
A clinical-stage biotech developing regenerative medicines for heart failure.
United Kingdom
N/A

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.